Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

February 25, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search